Platinum-induced Neurotoxicity: A Review of Possible Mechanisms

Overview

Journal World J Clin Oncol

Publisher Baishideng Publishing Group

Specialty Oncology

Date 2017 Aug 30

PMID 28848699

Citations 66

Authors

Ozkan Kanat

Hulya Ertas

Burcu Caner

Affiliations

Soon will be listed here.

Abstract

Patients treated with platinum-based chemotherapy frequently experience neurotoxic symptoms, which may lead to premature discontinuation of therapy. Despite discontinuation of platinum drugs, these symptoms can persist over a long period of time. Cisplatin and oxaliplatin, among all platinum drugs, have significant neurotoxic potential. A distal dose-dependent symmetrical sensory neuropathy is the most common presentation of platinum neurotoxicity. DNA damage-induced apoptosis of dorsal root ganglion (DRG) neurons seems to be the principal cause of neurological symptoms. However, DRG injury alone cannot explain some unique symptoms such as cold-aggravated burning pain affecting distal extremities that is observed with oxaliplatin administration. In this article, we briefly reviewed potential mechanisms for the development of platinum drugs-associated neurological manifestations.

Citing Articles

Role of RGS17 in cisplatin-induced cochlear inflammation and ototoxicity via caspase-3 activation.

Al Aameri R, Alanisi E, Al Sallami D, Alberts I, Tischkau S, Rybak L Front Immunol. 2025; 16:1470625.

PMID: 40061942 PMC: 11885124. DOI: 10.3389/fimmu.2025.1470625.

Synthesis of (1,10-Phenanthroline-,')(β-Methyl- and β-PhenylAlaninate-,)Copper(II) Nitrate Complexes and Their Antiproliferative Activity on MCF-7 and A549 Cancer Cell Lines.

Chavelas-Hernandez L, Hernandez-Vazquez L, Valdez-Camacho J, Espinoza-Guillen A, Tavira-Montalvan C, Meneses-Acosta A Molecules. 2025; 30(3).

PMID: 39942738 PMC: 11820680. DOI: 10.3390/molecules30030634.

Earnings and work loss after colon and rectal cancer: a Swedish nationwide matched cohort study.

Boman S, Hed Myrberg I, Bruze G, Martling A, Nordenvall C, Nilsson P EClinicalMedicine. 2024; 75:102770.

PMID: 39210942 PMC: 11359760. DOI: 10.1016/j.eclinm.2024.102770.

Neurological adverse events associated with oxaliplatin: A pharmacovigilance analysis based on FDA adverse event reporting system.

Pan X, Xiao X, Ding Y, Shu Y, Zhang W, Huang L Front Pharmacol. 2024; 15:1431579.

PMID: 39045045 PMC: 11263116. DOI: 10.3389/fphar.2024.1431579.

Effect of tangeretin on cisplatin-induced oxido-inflammatory brain damage in rats.

Cicek B, Danisman B, Bolat I, Kiliclioglu M, Kuzucu M, Suleyman H J Cell Mol Med. 2024; 28(14):e18565.

PMID: 39044287 PMC: 11265995. DOI: 10.1111/jcmm.18565.

References

Adelsberger H, Quasthoff S, Grosskreutz J, Lepier A, Eckel F, Lersch C . The chemotherapeutic oxaliplatin alters voltage-gated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol. 2000; 406(1):25-32. DOI: 10.1016/s0014-2999(00)00667-1. View

Cavaletti G, Tredici G, Petruccioli M, Donde E, Tredici P, Marmiroli P . Effects of different schedules of oxaliplatin treatment on the peripheral nervous system of the rat. Eur J Cancer. 2001; 37(18):2457-63. DOI: 10.1016/s0959-8049(01)00300-8. View

McDonald E, Randon K, Knight A, Windebank A . Cisplatin preferentially binds to DNA in dorsal root ganglion neurons in vitro and in vivo: a potential mechanism for neurotoxicity. Neurobiol Dis. 2005; 18(2):305-13. DOI: 10.1016/j.nbd.2004.09.013. View

Webster R, Brain K, Wilson R, Grem J, Vincent A . Oxaliplatin induces hyperexcitability at motor and autonomic neuromuscular junctions through effects on voltage-gated sodium channels. Br J Pharmacol. 2005; 146(7):1027-39. PMC: 1751225. DOI: 10.1038/sj.bjp.0706407. View

Ta L, Espeset L, Podratz J, Windebank A . Neurotoxicity of oxaliplatin and cisplatin for dorsal root ganglion neurons correlates with platinum-DNA binding. Neurotoxicology. 2006; 27(6):992-1002. DOI: 10.1016/j.neuro.2006.04.010. View

Pasetto L, Dandrea M, Rossi E, Silvio Monfardini . Oxaliplatin-related neurotoxicity: how and why?. Crit Rev Oncol Hematol. 2006; 59(2):159-68. DOI: 10.1016/j.critrevonc.2006.01.001. View

Krishnan A, Goldstein D, Friedlander M, Kiernan M . Oxaliplatin and axonal Na+ channel function in vivo. Clin Cancer Res. 2006; 12(15):4481-4. DOI: 10.1158/1078-0432.CCR-06-0694. View

Tomaszewski A, Busselberg D . Cisplatin modulates voltage gated channel currents of dorsal root ganglion neurons of rats. Neurotoxicology. 2006; 28(1):49-58. DOI: 10.1016/j.neuro.2006.07.005. View

Dzagnidze A, Katsarava Z, Makhalova J, Liedert B, Yoon M, Kaube H . Repair capacity for platinum-DNA adducts determines the severity of cisplatin-induced peripheral neuropathy. J Neurosci. 2007; 27(35):9451-7. PMC: 6673116. DOI: 10.1523/JNEUROSCI.0523-07.2007. View

10.

Alaedini A, Xiang Z, Kim H, Sung Y, Latov N . Up-regulation of apoptosis and regeneration genes in the dorsal root ganglia during cisplatin treatment. Exp Neurol. 2008; 210(2):368-74. DOI: 10.1016/j.expneurol.2007.11.018. View

11.

Jimenez-Andrade J, Herrera M, Ghilardi J, Vardanyan M, Melemedjian O, Mantyh P . Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol Pain. 2008; 4:10. PMC: 2289805. DOI: 10.1186/1744-8069-4-10. View

12.

Kagiava A, Tsingotjidou A, Emmanouilides C, Theophilidis G . The effects of oxaliplatin, an anticancer drug, on potassium channels of the peripheral myelinated nerve fibres of the adult rat. Neurotoxicology. 2008; 29(6):1100-6. DOI: 10.1016/j.neuro.2008.09.005. View

13.

Broomand A, Jerremalm E, Yachnin J, Ehrsson H, Elinder F . Oxaliplatin neurotoxicity--no general ion channel surface-charge effect. J Negat Results Biomed. 2009; 8:2. PMC: 2639537. DOI: 10.1186/1477-5751-8-2. View

14.

McWhinney S, Goldberg R, McLeod H . Platinum neurotoxicity pharmacogenetics. Mol Cancer Ther. 2009; 8(1):10-6. PMC: 2651829. DOI: 10.1158/1535-7163.MCT-08-0840. View

15.

Gauchan P, Andoh T, Kato A, Kuraishi Y . Involvement of increased expression of transient receptor potential melastatin 8 in oxaliplatin-induced cold allodynia in mice. Neurosci Lett. 2009; 458(2):93-5. DOI: 10.1016/j.neulet.2009.04.029. View

16.

Wu S, Chen B, Wu Y, Peng H, Chen L . The mechanism of the actions of oxaliplatin on ion currents and action potentials in differentiated NG108-15 neuronal cells. Neurotoxicology. 2009; 30(4):677-85. DOI: 10.1016/j.neuro.2009.04.010. View

17.

Ta L, Bieber A, Carlton S, Loprinzi C, Low P, Windebank A . Transient Receptor Potential Vanilloid 1 is essential for cisplatin-induced heat hyperalgesia in mice. Mol Pain. 2010; 6:15. PMC: 2848188. DOI: 10.1186/1744-8069-6-15. View

18.

Sittl R, Carr R, Fleckenstein J, Grafe P . Enhancement of axonal potassium conductance reduces nerve hyperexcitability in an in vitro model of oxaliplatin-induced acute neuropathy. Neurotoxicology. 2010; 31(6):694-700. DOI: 10.1016/j.neuro.2010.07.006. View

19.

Hill A, Bergin P, Hanning F, Thompson P, Findlay M, Damianovich D . Detecting acute neurotoxicity during platinum chemotherapy by neurophysiological assessment of motor nerve hyperexcitability. BMC Cancer. 2010; 10:451. PMC: 2936328. DOI: 10.1186/1471-2407-10-451. View

20.

Podratz J, Knight A, Ta L, Staff N, Gass J, Genelin K . Cisplatin induced mitochondrial DNA damage in dorsal root ganglion neurons. Neurobiol Dis. 2010; 41(3):661-8. PMC: 3031677. DOI: 10.1016/j.nbd.2010.11.017. View